Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate

From Wikipedia, the free encyclopedia
Combination of
Estradiol diundecylateEstrogen
Hydroxyprogesterone heptanoateProgestogen
Testosterone cyclohexylpropionateAndrogen; Anabolic steroid
Clinical data
Trade namesTrioestrine Retard
Other namesEDU/OHPH/TCHP
Routes of
Intramuscular injection

Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate (EDU/OHPH/TCHP), sold under the brand name Trioestrine Retard, is an injectable combination medication of estradiol diundecylate (EDU), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone cyclohexylpropionate (TCHP), an androgen/anabolic steroid.[1][2][3] It contained 2.25 mg EDU, 100 mg OHPH, and 67.5 mg TCHP in oil solution, was provided as ampoules, and was administered by intramuscular injection.[1][2][3][4][5] The medication was manufactured by Roussel and Théramex and was marketed by 1953.[6] It is no longer available.[7][8]

See also[edit]


  1. ^ a b Herschberg AD (10 October 1960). "[The menopause and the treatment of its disorders by a long-acting multihormone complex: trioestrine lente]". Gazette Médicale de France (in French). 67: 1987–96. ISSN 0016-5557. PMID 13713782.
  2. ^ a b Leszek Krówczyński (1987). Extended Release Dosage Forms. CRC Press. p. 13. ISBN 978-0-8493-4307-0. Hydroxyprogesterone heptanoate + testosterone cyclohexylpropionate + oestradiol undecanoate. Trioestrine-RetardR (Theramex). Oily solution for injection.
  3. ^ a b Axel Kleemann; Jürgen Engel (2001). Pharmaceutical substances: syntheses, patents, applications. Thieme. p. 1998. ISBN 978-3-13-558404-1.
  4. ^ Bordier, Philippe (1963). "Cure of fifteen osteoporosis cases by a delayed effect of hormonal association". Semaine des Hopitaux. 39 (2): 81–4. ISSN 0037-1777. The patients (females) received intramuscularly, every 10 days for 2-3 months, estradiol diundecyleate 2.25, testosterone cyclohexylpropionate 67.5, and hydroxyprogesterone heptylate 100 mg. ("trioestrine retard"). Their av. calcuria decreased 30.5% (0-69%) and asthenia, anorexia, and muscular activity improved.
  5. ^ France (1964). Journal officiel de la République française. Spécialité dénommée Trioestrine retard Theramex, soluté injectable I. M. : [...] Composition : heptylate d'hydroxy-17 alpha-progestérone, 10 g ; cyclohexyl propionate de testostérone, 10 g ; di-undécylate d'œstradiol, 0,5 g ; excipient Q. S. P. 100 ml (en boîtes de 2 ampoules de 1 ml).
  6. ^ France (March 1953). Journal officiel de la République française. pp. 2564–.
  7. ^ "Home".
  8. ^ [1][dead link]